Hematology: Follicular lymphoma: Maintenance therapy is (often) indicated

Nature Reviews Clinical Oncology

Volumn 6, Issue 11, 2009, Pages 624-626

  Seymour, John F ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOMODULATION; MAINTENANCE THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SALVAGE THERAPY; SINGLE DRUG DOSE; SURVIVAL TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HEMATOLOGY; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LYMPHOMA, FOLLICULAR; META-ANALYSIS AS TOPIC; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SALVAGE THERAPY; TIME FACTORS; VINCRISTINE;

EID: 70449427696     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.159     Document Type: Article

References (10)

1. Steward, W. P. et al. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 61, 441-447 (1988).
2. Rohatiner, A. Z. S. et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J. Clin. Oncol. 23, 2215-2223 (2005).
3. Ezdinli, E. Z. et al. The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. Cancer 60, 156-160 (1987).
4. Ghielmini, M. et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule. Blood 103, 4416-4423 (2004).
5. Hainsworth, J. D. et al. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research network. J. Clin. Oncol. 23, 1088-1095 (2005).
6. Hochster, H. et al. Maintenance rituximab after cyclophosphamide, vincristine and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study. J. Clin. Oncol. 27, 1607-1614 (2009).
7. van Oers, M. H. J. et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108, 3295-3301 (2006).
8. Forstpointner, R. et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108, 4003-4008 (2006).
9. Vidal, L. et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials. J. Natl Cancer Inst. 101, 248-255 (2009).
10. Gajraj, E., Chung, H., Longson, C. & Stevens, A. Rituximab for follicular non-Hodgkin lymphoma. Lancet Oncol. 9, 320-321 (2008).